peopleimages-2
peopleimages / iStockphoto.com
23 February 2018Americas

Takeda makes waves with neurological collaboration

Japan-based Takeda Pharmaceuticals has entered into a global strategic collaboration with Wave Life Sciences.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
29 August 2017   AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
3 April 2018   Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.

More on this story

Asia
29 August 2017   AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
3 April 2018   Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.

More on this story

Asia
29 August 2017   AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease.
Asia-Pacific
3 April 2018   Japan-based Takeda has revealed that it is considering plans to acquire biopharmaceutical company Shire.